<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000820</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 248</org_study_id>
    <secondary_id>11225</secondary_id>
    <nct_id>NCT00000820</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy</brief_title>
  <official_title>A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      PRIMARY: To examine the effect of aldesleukin ( IL-2 ) on viral activity in the blood. To&#xD;
      determine the safety of low-dose IL-2 in combination with antiretroviral therapy versus&#xD;
      antiretroviral therapy alone.&#xD;
&#xD;
      SECONDARY: To examine delayed type hypersensitivity responses to skin test antigens and&#xD;
      antibody responses to protein and polysaccharide vaccines.&#xD;
&#xD;
      The profound immune impairment that results from HIV-1 infection is due, at least in part, to&#xD;
      the loss of CD4+ T cells and the cytokines these cells secrete, especially IL-2 and&#xD;
      interferon-gamma. Antiretroviral agents do not directly address the problem of immune&#xD;
      impairment. Replacement of IL-2 at nontoxic doses may prevent or delay clinical&#xD;
      immunosuppression and its attendant opportunistic infections. Also, since patients with HIV-1&#xD;
      infection respond suboptimally to routine protein and polysaccharide immunizations, IL-2 may&#xD;
      provide an adjuvant effect on vaccine responses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The profound immune impairment that results from HIV-1 infection is due, at least in part, to&#xD;
      the loss of CD4+ T cells and the cytokines these cells secrete, especially IL-2 and&#xD;
      interferon-gamma. Antiretroviral agents do not directly address the problem of immune&#xD;
      impairment. Replacement of IL-2 at nontoxic doses may prevent or delay clinical&#xD;
      immunosuppression and its attendant opportunistic infections. Also, since patients with HIV-1&#xD;
      infection respond suboptimally to routine protein and polysaccharide immunizations, IL-2 may&#xD;
      provide an adjuvant effect on vaccine responses.&#xD;
&#xD;
      Patients are randomized initially to receive their own antiretroviral therapy alone or in&#xD;
      combination with IL-2 for 24 weeks, after which each group is crossed over to the other&#xD;
      treatment assignment (i.e., IL-2 is either added or deleted from the regimen) for an&#xD;
      additional 24 weeks. Patients who are vaccine eligible receive influenza, tetanus and&#xD;
      diphtheria toxoid, and meningococcal polysaccharide vaccines at week 4, and those who have&#xD;
      not received pneumococcal vaccine prior to study entry will receive it at week 8.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">March 2002</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>104</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  PCP prophylaxis.&#xD;
&#xD;
          -  Therapy for an opportunistic infection that develops on study, with the exception of&#xD;
             foscarnet for CMV disease or resistant Herpes simplex.&#xD;
&#xD;
          -  Systemic corticosteroids ONLY IF given for no longer than 21 days for acute PCP.&#xD;
&#xD;
          -  Topical corticosteroids to areas separate from a skin test or IL-2 injection site.&#xD;
&#xD;
          -  Acyclovir up to 1000 mg/day as maintenance for recurrent genital Herpes.&#xD;
&#xD;
          -  Erythropoietin and filgrastim.&#xD;
&#xD;
          -  Antiemetics.&#xD;
&#xD;
          -  Antibiotics as clinically indicated.&#xD;
&#xD;
          -  Elective standard immunizations at week 8 or later.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Local radiation therapy.&#xD;
&#xD;
        Prior Medication: Required:&#xD;
&#xD;
          -  Stable, approved antiretroviral therapy for at least 2 months (was 3 months, amended&#xD;
             3/26/96) prior to study entry.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV seropositivity.&#xD;
&#xD;
          -  CD4 count 300 - 700 cells/mm3.&#xD;
&#xD;
          -  Stable antiretroviral therapy for at least 2 months (was 3 months, amended 3/26/96)&#xD;
             prior to study entry.&#xD;
&#xD;
          -  No history of AIDS-defining illness except for limited cutaneous Kaposi's sarcoma.&#xD;
&#xD;
          -  Normal EKG (isolated nonspecific ST and T wave changes permitted).&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  This protocol is approved for prisoner participation.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Malignancy requiring systemic or local cytotoxic chemotherapy.&#xD;
&#xD;
          -  Untreated thyroid disease.&#xD;
&#xD;
          -  Asthma requiring intermittent or chronic inhalation or systemic therapy.&#xD;
&#xD;
          -  Any medical condition that precludes study entry.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antianginal agents such as nitrates, calcium channel blockers, beta blockers, and&#xD;
             antiarrhythmics.&#xD;
&#xD;
          -  Systemic or local cytotoxic chemotherapy.&#xD;
&#xD;
          -  Interferons.&#xD;
&#xD;
          -  Interleukins other than study drug.&#xD;
&#xD;
          -  Pentoxifylline ( Trental ).&#xD;
&#xD;
          -  Acetylcysteine ( NAC ).&#xD;
&#xD;
          -  Sargramostim ( GM-CSF ).&#xD;
&#xD;
          -  Dinitrochlorobenzene ( DCNB ).&#xD;
&#xD;
          -  Thymosin alpha 1.&#xD;
&#xD;
          -  Thymopentin.&#xD;
&#xD;
          -  Inosiplex ( Isoprinosine ).&#xD;
&#xD;
          -  Polyribonucleoside ( Ampligen ).&#xD;
&#xD;
          -  Ditiocarb sodium ( Imuthiol ).&#xD;
&#xD;
          -  Therapeutic HIV vaccines.&#xD;
&#xD;
          -  Investigational antiretroviral agents such as lamivudine ( 3TC ) and tat and protease&#xD;
             inhibitors.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Aspirin.&#xD;
&#xD;
          -  Immune globulin ( IVIG ).&#xD;
&#xD;
          -  Thalidomide.&#xD;
&#xD;
          -  Systemic corticosteroids (permitted for 21 days or less for PCP treatment only).&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Ongoing transfusion.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of autoimmune disease, including inflammatory bowel disease and psoriasis&#xD;
             (although autoimmune thyroid disease that is stable is allowed).&#xD;
&#xD;
          -  Clinically significant CNS disease or seizures that have been active within 1 year&#xD;
             prior to study entry.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  IL-2 within 3 months prior to study entry.&#xD;
&#xD;
          -  Any immunomodulatory therapy within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Foscarnet within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Acute therapy for an opportunistic infection within 14 days prior to study entry.&#xD;
&#xD;
        Active alcohol or substance abuse that would compromise study compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teppler H</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Pomerantz R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Therapeutics CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>462025250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY - Buffalo, Erie County Medical Ctr.</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med. Ctr. (Mt. Sinai)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University A2201</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>275997215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. of the Univ. of Pennsylvania CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, Schock B; AIDS Clinical Trials Group 248 Study Team. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). J Acquir Immune Defic Syndr. 2004 May 1;36(1):576-87. doi: 10.1097/00126334-200405010-00005.</citation>
    <PMID>15097300</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interleukin-2</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

